Last reviewed · How we verify
GLP-1RA
At a glance
| Generic name | GLP-1RA |
|---|---|
| Also known as | INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE |
| Sponsor | University of Virginia |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) (PHASE3)
- Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment (NA)
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (PHASE2)
- Probiotic Intervention on Body Weight (NA)
- Protein Supplementation Intervention on Body Weight (NA)
- A Cohort Study on Obese Patients' Multidisciplinary Integrated Health Management
- Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD) (NA)
- GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1RA CI brief — competitive landscape report
- GLP-1RA updates RSS · CI watch RSS
- University of Virginia portfolio CI